Mobile App information: All registered delegates will receive separate instructions on how to download the EAHAD 2020 Mobile App. To use the Mobile App, you will be required to register by completing a small questionnaire, which will allow you to make use of the implemented match-making system and take part in the voting & Q&A during sessions.
Multidisciplinary Pre-Congress Day | Programme as of 4 November 2019
12:00 – 13:00 | REGISTRATION AND LUNCH |
13:00 – 13:45 | JOINT SESSION: Insight into the care of patients with rare bleeding disorders in the Netherlands | |
---|---|---|
13:00 – 13:15 | Welcome and Introduction | K Fijn van Draat |
13:15 – 13:45 | Panel discussion:
Multidisciplinary and interdisciplinary care in the Netherlands: Differences, opportunities and challenges |
Chair: P de Kleijn
S Andeweg |
14:00 – 19:00 | NURSES SESSIONS |
---|
14:00 – 15:00 | SESSION 1: Nurse-led research: Stepping out of your comfort zone | Chair: S Fletcher |
---|---|---|
14:00 – 14:20 | How to create a good poster & how to choose a research topic | L Myrin Westesson |
14:20 – 14:55 | SLAM session | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14:55 – 15:00 | Interview and roundtable discussion with SLAM presenters | |
15:00 – 15:30 | Break |
15:30 – 17:00 | SESSION 2: Bleeding disorders within the family | Chair: S Grønhaug |
---|---|---|
15:30 – 16:00 | Family legacy: Theoretical input | G O’Brien |
16:00 – 16:30 | Family legacy: Learning from cases | N Uitslager |
16:30 – 17:00 | Patients’ perspective: Interview with two women with bleeding disorders | N Uitslager M van der Ven M Degenaar |
17:00 – 17:30 | Break |
17:30 – 19:00 | SESSION 3: Facilitating resilience and promoting mindfulness | Chair: M Kavanagh |
---|---|---|
17:30 – 18:20 | Facilitating resilience in nurses and patients | P Bučková |
18:20 – 19:00 | Closing remarks & Evaluation | E Müller-Kägi |
14:00 – 19:00 | PHYSIOTHERAPISTS SESSIONS |
---|
14:00 – 15:15 | SESSION 1: What are the challenges for the physiotherapist today? | Chair: R E Matlary |
---|---|---|
14:00 – 14:20 | Differentiating between osteoarthritis and haemophilic arthropathy | L Van Vulpen |
14:20 – 14:40 | Establishing a joint injection clinic – perspectives of the physiotherapist | M Bladen |
14:40 – 15:00 | Clinical implications of early detection of haemophilic arthropathy | L Van Vulpen |
15:00 – 15:15 | Discussion with the audience | |
15:15 – 15:30 | Break |
15:30 – 17:00 | SESSION 2: Free Paper session | Chair: S Lobet |
---|---|---|
15:30 – 16:40 | 10-minute Free Paper presentations | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16:40 – 16:55 | Discussion with the audience | |
16:55 – 17:00 | Announcement of the winners | |
17:00 - 17:15 | Break |
17:15 – 18:45 | SESSION 3: Hot Topic Debates | Chair: P McLaughlin |
---|---|---|
17:15 – 17:45 | Is ultrasound really helpful in clinical consultation or is it a trend? | M Aspdahl – YES, it is helpful D Stephensen – NO, it is a trend |
17:45 – 17:50 | Announcement of the winner | |
17:50 – 18:20 | Should haemophilia patients attend physiotherapy sessions in their own HTC? | E Mauser-Bunschoten – YES P de Kleijn – NO |
18:20 – 18:25 | Announcement of the winner | |
18:25 – 18:55 | “Give a man a fish and you feed him for a day; teach a man to fish and you feed him for life”: Manual therapy VS self-rehabilitation | T Flannery – Manual therapy S Lobet – Self-rehabilitation |
18:55 – 19:00 | Announcement of the winner |
14:00 – 19:00 | PSYCHOSOCIAL SESSIONS |
---|
14:00 – 15:20 | SESSION 1: Relevant issues regarding well-being from childhood to adulthood | Chair: A Torres Ortuño |
---|---|---|
14:00 – 14:30 | Children with bleeding disorders: what a child psychologist can do to help | K Vandenabeele |
14:30 – 14:40 | Questions and discussion | |
14:40 – 15:10 | My experience of running Wellbeing Workshops | C Burgess |
15:10 – 15:20 | Questions and discussion | |
15:20 – 15:50 | Break |
15:50 – 17:50 | SESSION 2: Psychological strategies to manage pain and promote sexual health | Chair: C Burgess |
---|---|---|
15:50 – 16:20 | Principles of pain management in haemophilia patients | G Golan |
16:20 – 16:30 | Questions and discussion | |
16:30 – 17:00 | EMDR used for pain management | C de Roos |
17:00 – 17:10 | Questions and discussion | |
17:10 – 17:40 | Sexuality and haemophilia | E Laan |
17:40 – 17:50 | Questions and discussion | |
17:50 – 18:20 | Break |
18:20 – 19:00 | SESSION 3: Shaping psychosocial haemophilia care in Europe | Chair: L Haverman |
---|---|---|
18:20 – 18:50 | Brainstorming session on building a network of psychosocial professionals in Europe: What can the EAHAD Psychosocial Group do for you? | All |
18:50 – 19:00 | Closing remarks | L Haverman |
19:00 – 21:00 | Networking Reception Dinner |
09:30 – 11:00 | MULTIDISCIPLINARY EDUCATIONAL SESSION: Managing Woman-Specific Bleeding Issues |
Chairs:
K van Galen |
---|---|---|
09:30 – 10:15 | Case 1 – Adolescent woman with an inherited bleeding disorder (BD) – Life stage challenges | |
|
|
|
|
|
|
|
|
|
10:15 – 11:00 | Case 2 – Adult woman with an inherited BD who is actively trying to get pregnant | |
|
|
|
|
|
|
|
|
|
11:00 – 11:30 | Coffee Break |
11:30 – 18:30 | INDUSTRY SPONSORED SESSIONS |
---|---|
11:30 – 12:45 | Industry sponsored sessions |
12:45 – 13:45 | Lunch Break |
13:45 – 15:00 | Industry sponsored sessions |
15:00 – 15:30 | Coffee Break |
15:30 – 16:45 | Industry sponsored sessions |
16:45 – 17:15 | Coffee Break |
17:15 – 18:30 | Industry sponsored sessions |
18:30 – 19:30 | Welcome Reception and Poster Presentations |
08:30 – 08:45 | Welcome and Introduction | K Fijn van Draat
M Makris |
---|
08:45 – 09:15 | SESSION 1: Next Nature | |
---|---|---|
08:45 – 09:15 | Next Nature – Why Technology Is Our Natural Future | K van Mensvoort |
09:15 – 10:45 | SESSION 2: Therapeutic Landscapes | Chairs:
F Peyvandi |
---|---|---|
09:15 – 09:45 | Current therapeutic landscape for haemophilia | F Peyvandi |
09:45 – 10:15 | Future therapeutic landscape for haemophilia | P Collins |
10:15 – 10:45 | Gene therapy | W Miesbach |
10:45 – 11:15 | Coffee Break/Poster Viewing |
11:15 – 13:00 | SESSION 3: Dilemmas in PUPs and Paediatric Patients | Chairs:
H Chambost |
---|---|---|
11:15 – 11:30 | Case presentation: Clinical dilemmas in a newborn with haemophilia A | N Gretenkort Andersson |
11:30 – 12:00 | PUP treatment and immune tolerance induction treatment | M Mancuso |
12:00 – 12:30 | Gene therapy for children, ethical aspects | R van der Graaf |
12:30 – 13:00 | Uncertainties in the era of new treatments: What patients think the safeguards should be | C Smit |
13:00 – 14:00 | Lunch Break/Poster Viewing/EAHAD Annual General Meeting |
14:00 – 15:30 | SESSION 4: Diagnostic Discoveries | Chairs:
W Miesbach |
---|---|---|
14:00 – 14:30 | Future diagnostics of platelet disorders | K Freson |
14:30 – 15:00 | Predicting joint damage | L van Vulpen |
15:00 – 15:30 | Monitoring novel therapeutics | P Lenting |
15:30 – 16:00 | Break |
16:00 – 17:45 | SESSION 5: Von Willebrand Factor/Disease: Throughout Real Life | Chair:
R Lassila |
---|---|---|
16:00 – 16:15 | Case presentation: Clinical dilemmas in a patient with VWD | M Kruip |
16:15 – 16:45 | Circle of life of VWD patients | F Leebeek |
16:45 – 17:15 | Low VWF | M Lavin |
17:15 – 17:45 | PK of perioperative treatment in VWD patients | G Castaman |
19.00 – 23:00 | Networking Evening |
08:30 – 10:00 | SESSION 6: SLAM | Chairs:
M Makris V Jiménez Yuste |
---|---|---|
OR01 | FIFTY YEARS OF HEMOPHILIA IN THE NETHERLANDS | S Hassan |
OR02 | TREATMENT OF GIRLS AND WOMEN WITH HAEMOPHILIA A AND HAEMOPHILIA B: A RETROSPECTIVE STUDY IN THE FRANCECOAG COHORT | M Viprey |
OR03 | THE TREATMENT HISTORY OF NON-SEVERE HEMOPHILIA A | F R Kloosterman |
OR04 | REPORT ON THE ANNUAL GLOBAL SURVEY – 20 YEARS ON AND MORE INFORMATIVE | A Iorio |
OR05 | IMPACT OF HEPATITIS C INFECTION ON BONE MICROSTRUCTURE OF PATIENTS WITH HAEMOPHILIA (PWH) | K Holstein |
OR06 | POPULATION PHARMACOKINETIC MODELLING OF VON WILLEBRAND FACTOR ACTIVITY LEVELS DURING PERIOPERATIVE DOSING OF A VWF/FVIII CONCENTRATE IN VON WILLEBRAND DISEASE | L H Bukkems |
OR07 | PHASE 2B TRIAL TO EVALUATE THE SAFETY AND FACTOR IX LEVELS RESULTING FROM A DAILY SUBCUTANEOUS PROPHYLAXIS TREATMENT REGIMEN OF DALCINONACOG ALFA (DALCA) IN HEMOPHILIA B | J Mahlangu |
OR08 | FITUSIRAN, AN RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA: MANAGEMENT OF BREAKTHROUGH BLEEDING EVENTS | S W Pipe |
OR09 | RURIOCTOCOG ALFA PEGOL PK-GUIDED PROPHYLAXIS TARGETING TWO FVIII TROUGH LEVELS IN SEVERE HEMOPHILIA A PATIENTS (PROPEL PHASE 3 STUDY): IMPACT OF PATIENT FVIII HALF-LIFE ON CONSUMPTION AND EFFICACY OUTCOMES | J Windyga |
OR10 | ONE YEAR DATA FROM A PHASE 2B TRIAL OF AMT-061 (AAV5-PADUA HFIX VARIANT), AN ENHANCED VECTOR FOR GENE TRANSFER IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B | S W Pipe |
10:00 – 10:30 | Coffee Break/Poster Viewing |
10:30 – 11:30 | SESSION 7: Debate: Do we really need PK-based management? | Chairs:
J Blatny |
---|---|---|
YES, PK improves outcomes | M Cnossen | |
NO, we don’t need PK to improve outcomes | D Hart |
11:30 – 12:00 | EAHAD Update | Chair:
C Hermans |
---|---|---|
11:30 – 12:00 | EAHAD European Activities Update | M Makris |
12:00 – 12:30 | Arosenius Lecture 2020 |
Chairs: R Klamroth F Baghaei |
---|---|---|
Haemophilia care in Europe | B O’Mahony | |
12:30 – 13:15 | Lunch Break |
13:15 – 14:00 | Poster and Research Awards | Chairs:
F Peyvandi |
---|---|---|
13:15 – 13:35 | Reports from 2018 Research Grant winners: | |
|
|
|
|
|
|
13:35 – 14:00 | Award presentations |
14:00 – 15:00 | SESSION 8: Hot Topics | Chairs:
F Peyvandi |
---|---|---|
FIRST-IN-HUMAN GENE THERAPY STUDY OF AAVhu37 CAPSID VECTOR TECHNOLOGY IN SEVERE HAEMOPHILIA A: SAFETY AND FVIII ACTIVITY RESULTS |
S W Pipe | |
PHASE 1/2 INTERIM DATA FROM B-AMAZE STUDY OF ADENO ASSOCIATED VIRUS (AAV) GENE THERAPY (FLT180A) CONFIRMS PROGRESS TOWARDS ACHIEVING FACTOR IX LEVELS IN THE NORMAL RANGE FOR PATIENTS WITH SEVERE OR MODERATELY SEVERE HAEMOPHILIA B |
P Chowdary | |
ANTI-TFPI ANTIBODY BAY 1093884: EARLY TERMINATION OF PHASE II DOSE ESCALATION STUDY DUE TO THROMBOSIS |
M E Mancuso | |
SUMMARY OF THROMBOEMBOLIC (TE) OR THROMBOTIC MICROANGIOPATHY (TMA) EVENTS IN PERSONS TAKING EMICIZUMAB |
R Ko |
15:00 – 15:15 | Closing Remarks | K Fijn van Draat |
---|